Feline injection-site sarcoma: Past, present and future perspectives

Feline injection-site sarcomas (FISS) have been known since the early 1990s. After an initial correlation with rabies and feline leukaemia virus vaccination, subsequent studies have demonstrated that an abnormal reaction of feline tissues to chronic inflammation was mainly responsible for the diseas...

Full description

Saved in:
Bibliographic Details
Published in:The veterinary journal (1997) 2011-05, Vol.188 (2), p.136-141
Main Authors: Martano, Marina, Morello, Emanuela, Buracco, Paolo
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - therapeutic use
Cat Diseases - diagnosis
Cat Diseases - therapy
Cats
Chemotherapy
Chemotherapy, Adjuvant - veterinary
Combined Modality Therapy - veterinary
drug therapy
etiology
Feline injection-site sarcomas
Feline leukemia virus
image analysis
immune system
immunomodulators
Inflammation
injection site
Injections - adverse effects
Injections - veterinary
metastasis
Neoplasm Recurrence, Local
pathogenesis
planning
rabies
Radiotherapy
sarcoma
Sarcoma - diagnosis
Sarcoma - therapy
Sarcoma - veterinary
Soft Tissue Neoplasms - diagnosis
Soft Tissue Neoplasms - therapy
Soft Tissue Neoplasms - veterinary
Surgery
Tomography, X-Ray Computed
Treatment Outcome
vaccination
Vaccination - adverse effects
Vaccination - veterinary
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Feline injection-site sarcomas (FISS) have been known since the early 1990s. After an initial correlation with rabies and feline leukaemia virus vaccination, subsequent studies have demonstrated that an abnormal reaction of feline tissues to chronic inflammation was mainly responsible for the disease. The low incidence of FISS in the population is explained by its multifactorial aetiology, since individual genetic characteristics are also implicated. FISS is an infiltrative tumour with low metastatic potential but local recurrence is common. Multimodal treatment (extensive surgery, radiotherapy, chemotherapy) is recommended. The use of sophisticated imaging techniques can improve diagnosis and help in surgical planning. After the initial enthusiasm in understanding the disease, only few advances have been made in the last few years. New promising therapies may arise from a better knowledge of the molecular pathogenesis of FISS and the successful development of drugs modulating the immune system.
ISSN:1090-0233
1532-2971
DOI:10.1016/j.tvjl.2010.04.025